Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.
|
| Abstract |
High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride, an inhibitor of several transporters involved in multidrug resistance of cancer cells, which demonstrated an enhancement of the ability of cisplatin to induce apoptosis. In this work, we co-administrated acetazolamide, a carbonic anhydrase isoform IX (CAIX) inhibitor which was reported to increase chemotherapy efficacy in various cancer types, to the cisplatin/fendiline approach in SKNBE2 xenografts in NOD-SCID mice with the aim of identifying a novel and more effective treatment. We observed that the combination of the three drugs increases more than twelvefold the differences in the cytotoxic activity of cisplatin alone, leading to a remarkable decrease of the expression of malignancy markers. Our conclusion is that this approach, based on three FDA-approved drugs, may constitute an appropriate improvement of the pharmacological approach to HR-NB.
|
|---|---|
| Authors | Patrizia Garbati, Raffaella Barbieri, Matilde Calderoni, Francesca Baldini, Mario Nizzari, Paola Modesto, Tullio Florio, Aldo Pagano |
| Journal | International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 13 (Jun 23 2021) ISSN: 1422-0067 [Electronic] Switzerland |
| PMID | 34201814 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!